Anthracyclines during pregnancy: embryo–fetal outcome in 160 patients

Germann, N.; Goffinet, François; Goldwasser, François

doi:10.1093/annonc/mdh009

Cited by 157 publications

(88 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, Peccatori and colleagues [66] support that epirubicin is preferable clinically in this setting given its better therapeutic index, fewer systemic and cardiac toxic effects, and shorter terminal halflife. These same authors relay their experience with epirubicin-based regimens for pregnancy-associated breast cancer and report no severe maternal or fetal complications, only one case of vesicoureteral reflux, mirroring other authors' experiences [66][67][68].…”

Section: Systemic Therapysupporting

confidence: 52%

Pregnancy-Associated Breast Cancer: A Literature Review

Barnes

Newman

2007

Surgical Clinics of North America

View full text Add to dashboard Cite

Breast cancer, along with cervical cancer, is one of the most commonly diagnosed cancers of pregnancy. Most would define gestational breast cancer as breast cancer that is diagnosed during pregnancy, lactation, and up to 12 months post-partum. The diagnostic and therapeutic implications in this clinical setting are special. These women typically present with a more advanced-stage disease that carries an associated poorer prognosis. Physicians thus are challenged to balance aggressive maternal care with appropriate modifications that will ensure fetal protection. . Of women diagnosed with breast cancer younger than 40 years, only approximately 10% will be pregnant [2,3]. These data certainly suggest a low incidence of pregnancy-associated breast cancer. In fact, historically, the incidence is estimated at 1 in 3000 pregnancies [4][5][6]. Despite the overall low incidence, however, gestational breast cancer is one of the most common pregnancy-associated malignancies, second only to cervical cancer [4,6]. Notably, many have offered that this incidence will only increase as more women delay childbearing until later in life [4,7]. This concern is based on the fact that pregnancy-associated breast cancer is age-related, and women

show abstract

Section: Systemic Therapysupporting

confidence: 52%

Pregnancy-Associated Breast Cancer: A Literature Review

Barnes

Newman

2007

Surgical Clinics of North America

View full text Add to dashboard Cite

show abstract

“…The incidence was lowered to 6% if folate antagonists were used in combination with chemotherapy. It has been shown that adjuvant or neoadjuvant chemotherapy of breast cancer patients with antracycline (FAC protocol) can be given relatively safely in second and third trimestre of pregnancy [20,21]. There are limited data on the use of taxanes, or trastusumab in pregnacy, so if indicated, they should be administrated in postpartal period, as well as radiation or endocrine therapy [22] In a study by Mulvihill et al [23], it was found that the children born to women who have conceived after cytotoxic therapy, did not appear to be at higher risk for congenital anomalies.…”

Section: Chemotherapymentioning

confidence: 99%

Fertility after breast cancer treatment

Kasum

Beketić-Orešković

Peddi

et al. 2014

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

“…The few studies that looked at the cardiac effect of chemotherapy in the foetus showed that acute myocardial dysfunction can appear during pregnancy with anthracyclines. (Cardonick and Lacobucci, 2004;Germann et al, 2004). However, follow-up with cardiac ultrasound in 81 children who received anthracycline treatment in utero (age 9 -29 years, mean 17 year) was reassuring (Aviles et al, 2006).…”

Section: Postpartummentioning

confidence: 99%